
June 27 (Reuters) - Mabwell Shanghai Bioscience Co Ltd 688062.SS:
MABWELL ANNOUNCES NOVEL DRUG TECHNOLOGY LICENSE AGREEMENT WITH QILU PHARMACEUTICAL FOR ALBIPAGRASTIM ALFA FOR INJECTION
MABWELL SHANGHAI BIOSCIENCE - QILU PHARMACEUTICAL GRANTED EXCLUSIVE RIGHTS FOR LICENSED PRODUCT IN GREATER CHINA
MABWELL SHANGHAI BIOSCIENCE CO LTD - T-MAB TO RECEIVE UP TO RMB 500 MILLION IN PAYMENTS